Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CYP4B1 | P13584 | 1/20 | 0.37 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.37 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.37 |
| ▸ | CYP2A7 | P20853 | 1/20 | 0.37 |
| ▸ | CYP3A7 | P24462 | 1/20 | 0.37 |
| ▸ | CYP2F1 | P24903 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12250910 | 0.85 | KIF11 (0.43) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL30777597 | 0.85 | KIF11 (0.43) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL533475 | 0.84 | DRD1 (0.35) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL534246 | 0.82 | SLC13A5 (0.44) | KCNH2SCN10AXDHDYRK1A | |
| SCHEMBL533719 | 0.79 | CYP3A4 (0.55) | ALDH1A1CYP1A1CYP1A2CYP2E1CYP3A4 | |
| SCHEMBL533636 | 0.79 | RIPK1 (0.37) | KDM4EMEN1ALDH1A1KMT2AKIF11 | |
| SCHEMBL22127721 | 0.78 | ABL1 (0.56) | CYP1A1CYP1A2CYP2E1CYP3A4CYP2C8 | |
| SCHEMBL260934 | 0.76 | KIF11 (0.47) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL8478981 | 0.75 | ABL1 (0.58) | KDM4EMEN1ALDH1A1HPGDKMT2A | |
| SCHEMBL534325 | 0.75 | RXRA (0.58) | KDM4EALDH1A1HPGDCYP3A4RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108107676-A | Chemically amplified positive resist film laminated body and pattern formation method | 信越化学工业株式会社 | 2018-06-01 | — | — | CN | disclosed |
| CN-107615168-A | Radiation-sensitive composition | 日产化学工业株式会社 | 2018-01-19 | — | — | CN | disclosed |
| CN-103797418-B | A kind of negative light-sensitive resin combination, pattern formation method, cured film, dielectric film, colour filter and display device | 东京应化工业株式会社 | 2017-06-13 | — | — | CN | disclosed |
| CN-106610566-A | Chemically amplified positive resist composition and patterning process | 信越化学工业株式会社 | 2017-05-03 | — | — | CN | disclosed |
| EP-2415763-B1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | UBE INDUSTRIES (JP) | 2016-01-27 | — | — | EP | disclosed |
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE INDUSTRIES, LTD. (JP) | 2014-04-24 | — | — | US | disclosed |
| US-8648097-B2 | Pyridylaminoacetic acid compound | UBE INDUSTRIES, LTD. (JP) | 2014-02-11 | — | — | US | disclosed |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | UBE INDUSTRIES, LTD. (JP) | 2012-07-26 | — | — | US | disclosed |
| EP-2415763-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING OR PREVENTING GLAUCOMA | Ube Industries, Ltd. (JP) | 2012-02-08 | — | — | EP | disclosed |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | UBE CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| EP-2264009-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | Ube Industries, Ltd. (JP) | 2010-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140113907-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KDM4E 2779/4885MEN1 4120/4885ALDH1A1 204/4885 |
| US-20110054172-A1 | PYRIDYLAMINOACETIC ACID COMPOUND | PTGER2, PTGER1, PTGDR2 | KDM4E 2804/4885MEN1 4385/4885ALDH1A1 256/4885 |
| US-20120190852-A1 | MEDICAL COMPOSITION FOR TREATMENT OR PROPHYLAXIS OF GLAUCOMA | F12, C1S, AKR1C3 | KDM4E 3706/4885MEN1 1413/4885ALDH1A1 377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.